Events

Investors



Corporate Profile

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Recent News

More »
DateTitle 
08/02/16Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2016. "We look forward to announcing the topline results for the first of two Phase 3 studies of fostamatinib in patients with ITP by the end of this August, followed by the second study's results a few months later," said Raul Rodriguez, president... 
Printer Friendly Version
07/26/16Rigel Announces Conference Call and Webcast to Report Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., July 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2016 financial results after market close on Tuesday, August 2, 2016.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-293... 
Printer Friendly Version
06/02/16Rigel to Present at Jefferies 2016 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 10:30 am ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live web... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.61
Change (%) - 0.09 (3.33%)
Volume851,661
Data as of 08/26/16 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $2.61 with a 52 week high of $3.68 and a 52 week low of $1.88.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.